Browse Articles

Filter By:

  • The past 5–10 years have seen rapid advances in digital sensors and imaging-based technologies for the diagnosis of neurological conditions. However, the majority of these technologies are in the early stages of development — now is the time to consider how we validate these tools and safely integrate them into clinical practice.

    • Cristina Granziera
    • Tim Woelfle
    • Ludwig Kappos
  • A growing number of clinical practice guidelines are being developed for neurological diseases, and they have the potential to benefit patients, clinicians, policymakers and payers. However, the effectiveness of these guidelines has not been evaluated, so we do not yet know whether they improve patient outcomes in a real-world setting.

    • Maurizio A. Leone
    • Joao Costa
  • The prominence of gastrointestinal dysfunction among the non-motor features of Parkinson disease (PD) indicates a close bidirectional link between the brain and the gut. This Review discusses the proposed roles of gut-related factors in PD development, progression and treatment responses, and as therapeutic targets.

    • Ai Huey Tan
    • Shen Yang Lim
    • Anthony E. Lang
    Review Article
  • Neurological diseases cause a massive burden, which will increase as populations age. Rapid advances in our understanding of disease mechanisms must be translated into human benefits. We cannot stop once technologies have been developed, but must ensure that evidence and pipelines are in place for their implementation to reduce burden and inequalities.

    • Anthony G. Marson
  • A new study has shown that a modulator of metabotropic glutamate receptor 5 can reverse synapse loss in mouse models of Alzheimer disease and has the potential to be developed as a disease-modifying treatment for this condition.

    • Heather Wood
    Research Highlight
  • In this Review, Oh and Bar-Or provide an overview of selected emerging therapies for multiple sclerosis with the potential to limit non-relapsing, progressive disease injury and to promote tissue repair, thereby addressing crucial unmet therapeutic needs.

    • Jiwon Oh
    • Amit Bar-Or
    Review Article
  • In this Perspective, the authors present their vision for a closed-loop system for automatic symptom monitoring and levodopa administration in individuals with Parkinson disease. The system would capitalize on the ongoing advances in wearable sensor technology, drug delivery systems and machine learning.

    • Hazhir Teymourian
    • Farshad Tehrani
    • Joseph Wang
  • A new genome-wide association study has identified 41 previously unknown loci associated with Alzheimer disease. However, these data provide limited insight into disease mechanisms or benefits for clinical prediction of Alzheimer disease.

    • Christina M. Lill
    • Lars Bertram
    News & Views
  • A new study provides evidence that inflammation protects against the development of chronic pain in people with acute back pain, and that anti-inflammatory drugs used to treat acute pain could do more harm than good in the long term.

    • Heather Wood
    Research Highlight
  • On the basis of a coverage decision for anti-amyloid monoclonal antibodies recently issued by the US Centers for Medicare and Medicaid Services, Medicare will offer ‘coverage with evidence development’ to allow more information on the clinical benefits of these antibodies to be gathered. Here, we discuss the implications of this decision for future clinical trials and Alzheimer disease care.

    • David Knopman
    • Mary Sano
    • Howard H. Feldman
  • A new paper published in Neuron presents an analysis of mRNA expression in human and mouse trigeminal ganglia at single-nucleus resolution. The resulting resource is thought-provoking and suggests new targets for pain therapies; however, the findings should be interpreted in the context of the available protein data and warrant functional verification.

    • Lars Edvinsson
    • Jacob C. A. Edvinsson
    • Kristian A. Haanes
    News & Views
  • Recent technological advances have enabled the detection of specific forms of phosphorylated tau in blood. Here, the authors summarize the performance of blood phosphorylated tau biomarkers in the context of Alzheimer disease and highlight related ethical, analytical and clinical challenges.

    • Thomas K. Karikari
    • Nicholas J. Ashton
    • Henrik Zetterberg
    Review Article